Abstract. BELLO, Ariel et al. Splenic marginal zone lymphoma. Acta Med Colomb [online]. , vol, n.1, pp ISSN Non-Hodgkin. Splenic marginal zone lymphoma is a rare, indolent B-cell non-Hodgkin lymphoma characterized by abnormal clonal proliferation of mature B- lymphocytes with. Monoterapia com rituximab no linfoma da zona marginal esplênico com linfócitos vilosos: relato de dois casos de pacientes com controle prolongado da doença.
|Published (Last):||5 November 2005|
|PDF File Size:||14.36 Mb|
|ePub File Size:||14.14 Mb|
|Price:||Free* [*Free Regsitration Required]|
Analysis of immunoglobulin genes in splenic marginal zone lymphoma suggests ongoing mutation. It needs to be emphasized that the evidence to support this approach is based marginap on case reports, since there are no randomized clinical trials on this subject. For management of symptomatic SMZL, splenectomy is still considered to be the front-line treatment of choice, since this treatment has shown survival advantage over chemotherapy.
In these review, the characteristics important for the diagnosis and categorisation of B-cell lymphomas will be summarised. September 27, Conflict of interest: The aim of any lymphoma classification is to provide an international language allowing communication.
Procesos linfoproliferativos no Hodgkin de células B
Median response duration was 21 months range 4 to 37 months. Furthermore it could constitute an alternative to splenectomy in older patients. Pueden registrarse remisiones prolongadas en los tumores de bajo grado. ZAP expression as a surrogate for immunoglobulin-variable-region mutations marginzl chronic lymphocytic leukemia. There are no specific treatment guidelines for patients for whom splenectomy fails to provide lintoma cure. Rituximab monotherapy also controlled the autoimmune thrombocytopenia in one patient.
Detection by the fluorescence in situ hybridization technique of MYC eslenico in paraffin-embedded lymphoma biopsy samples. Pacientes con F o FC con o sin Rituximab: The way in which cases of recurrence of splenic marginal zone lymphoma after splenectomy should be managed is still not fully established. All the contents of this journal, except where otherwise noted, is licensed under a Creative Commons Attribution License.
No lymphadenopathy was found from computed tomography CT scans at this time.
Splenic lymphoma with villous lymphocytes: June Pages SMZL is an indolent lymphoma usually treated by splenectomy. The category of diffuse large B-cell lymphoma is heterogeneous, including several subtypes.
However, a few patients relapse and the second-line treatment remains questionable. This item has received. Fludarabine is effective in the treatment of SLVL and should be considered as both a first-line therapeutic option as well as salvage therapy in this condition. However it carries significant complications, especially in elderly patients. Ausencia de t 11; 14o t 14; The Integruppo Italiano Linfomi IIL carried out a study to assess the outcomes of splenic marginal zone lymphoma and to identify prognostic factors in patients.
A year-old woman was diagnosed with SMZL in Aprilwith enlarged lymph nodes in the left cervical region. Unique phenotypic profile of monocytoid B cells: A longer follow-up and the study of a larger group of patients are warranted to confirm our findings.
Ten additional patients underwent splenectomy, and 17 patients were in the observation group. Prognostic value of numerical chromosome aberrations in multiple myeloma: A biopsy revealed recurrence of the lymphoma.
Valorar profilaxis con fluconazol mg po. Marginal zone B-cell lymphoma: The present study demonstrates that rituximab is an effective treatment for SMZL and could be considered as a substitute or alternative to splenectomy.
Considering the lack of established data regarding this rare and clinically challenging issue, we made a systematic search for indexed articles published on this topic. Curr Treat Lla Oncol. Previous article Next article.
LEZM – Linfoma Esplénico de la Zona Marginal
It should be noted that a broader search strategy was used in relation to these last two databases Table 1. SJR uses a similar algorithm as the Google page rank; it provides a quantitative and lonfoma measure of the journal’s impact.
Cytogenetic studies in seventy-six cases of B-chronic lymphoproliferative disorders. Interestingly, in addition to a relevant percentage of hematological remission, some patients also experienced a molecular remission. Unmutated immunoglobulin variable heavy-chain gene status remains an adverse prognostic factor after zon stem cell transplantation for chronic lymphocytic leukemia. SMZL was confirmed in 70 patients.